• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Halpern Tucker R. claimed ownership of 146,698 shares (SEC Form 3)

    1/8/24 5:30:45 PM ET
    $CMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Halpern Tucker R.

    (Last) (First) (Middle)
    P.O. BOX 540

    (Street)
    PORTSMOUTH NH 03802

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/27/2023
    3. Issuer Name and Ticker or Trading Symbol
    Comera Life Sciences Holdings, Inc. [ CMRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Member of 10% owner group
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 146,698 I By Trust(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants to Purchase Common Stock 02/01/2024 07/31/2028 Common Stock 256,723 $0.6135 I By Trust(1)
    Warrants to Purchase Common Stock 09/11/2023 09/11/2028 Common Stock 110,024 $0.6135 I By Trust(1)
    Warrants to Purchase Common Stock 12/29/2023 12/29/2028 Common Stock 1,090,908 $0.055 I By Trust(1)
    12.0% Senior Secured Convertible Notes 12/29/2023 12/29/2024 Common Stock 545,454 $0.055 I By Trust(1)
    Explanation of Responses:
    1. Held by Tucker R. Halpern 2020 Trust, of which the reporting person is the trustee.
    /s/ Tucker R. Halpern 01/08/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Campbell Michael Gerard bought $708 worth of shares (10,000 units at $0.07), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      11/28/23 4:25:36 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Financials

    Live finance-specific insights

    See more
    • Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

      – Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

      11/9/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

      – Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

      8/10/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

      – Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) --  Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende

      5/11/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Comera Life Sciences Holdings Inc.

      SC 13D - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      1/5/24 7:16:15 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13D/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/7/23 8:05:22 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13G/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/6/23 4:24:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:18 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:27 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:16 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

      WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to

      1/4/24 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Announces Process Exploring Strategic Alternatives

      WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a

      12/6/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Konar Shameek

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:48:13 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Konar Shameek claimed ownership of 1,001,064 shares (SEC Form 3)

      3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:47:03 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Denny George P Iii

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      1/11/24 7:14:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

      Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please

      4/11/23 9:04:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer

      WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te

      11/9/22 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care